OPKO HEALTH, INC. (OPK) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, OPKO HEALTH, INC.'s filing signal continuing negative.

OPKO Health, Inc. is a diversified healthcare company with operations spanning pharmaceuticals and diagnostics. Its pharmaceutical segment focuses on NGENLA(R) (somatrogon-ghla), a once-weekly human growth hormone injection with approvals in over 50 markets, and Rayaldee, a treatment for secondary hyperparathyroidism in adults with chronic kidney disease, authorized in 11 European countries. The company also develops innovative multi-specific immune therapies for cancer and infectious diseases through its subsidiary, ModeX Therapeutics, Inc. OPKO's diagnostics business, BioReference Health, LLC, has been strategically realigned to focus on its core clinical testing operations and specialty products, including the 4Kscore(R) prostate cancer test, following significant divestitures in 2024 and 2025. The company operates established pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, contributing to cash flow and facilitating market entry for its products.

Revenue is driven by sales of pharmaceutical products like NGENLA(R) and Rayaldee, along with revenue from intellectual property transfers, including milestone payments, royalties, and gross profit shares from collaborations with partners like Pfizer, Merck, and Eli Lilly. The diagnostics segment generates revenue from laboratory testing services, with a focus on specialty tests like the 4Kscore(R) test.